Brochure
Biologics Brochure
Summary: Explore our suite of proprietary technology platforms and range of integrated development, manufacturing and clinical supply services. Catalent Biologics partners with leading biologic and...
View Now
Brochure
OneBio® Suite
Summary: OneBio™Suite is a single solution integrating development through complete clinical and commercial supply to simplify, accelerate and de-risk...
View Now
Article
How to Choose the Best CDMO Partner for Your Biologic Development
Summary: Many, if not most, small and midsized biopharma companies choose to partner with outside vendors—contract development and manufacturing organization, or CDMOs—to handle their end-to-end biologic...
View Now
White Papers
Development Of An Intensified Fed-Batch Process Utilizing N-1 Perfusion And Ambr®15
Summary: While traditional fed-batch bioreactor process development has been well defined using methods such as shake flasks and bench-scale bioreactors, there is a desire to intensify...
View Now
eBook
Strategies For Speeding Time To Clinic For Biotherapeutics
Summary: As the need for accelerated biopharmaceutical development around the world continues to grow, companies are facing complex challenges that need to be overcome to remain competitive for increasing process productivity...
View Now
Article
Beating the Clock - Case Studies in Expediting Biologic Development
Summary: Biologic drug development is complex, requiring broad capabilities and expertise to ensure the highest likelihood of regulatory approval and commercial success. The journey from cell line development...
View Now
Article
Avoiding Delays on the Pathway to Clinic
Summary: Time is of the essence in the biopharmaceutical industry. How can developers ensure they get to the clinic as efficiently and smoothly as possible?
View Now
White Papers
Rapid Global Characterization of Immunoglobulin G1 Following Oxidative Stress
Summary: In this whitepaper, we describe a method for rapid and consistent global characterization of leachable metals- or peroxide-stressed immunoglobulin (Ig) G1 monoclonal antibodies (mAbs).
View Now
White Papers
Biophysical Characterization of a Therapeutic mAb and its Associated Antigen-Binding Fragments
Summary: Changes during purification, formulation, fill-finish, and distribution can affect protein stability and practically all steps in the manufacturing process may perturb the higher-order structure and heterogeneity of the molecule...
View Now
Webinars
Development Strategies for Difficult to Express Proteins
Summary: Biopharmaceutical products in development continue to increase in complexity. These include numerous multi-specific antibody platforms, proteins that require cleavage, or other additional post-translational modifications...
View Now